News

Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly's Zepbound
An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...
Tariffs Are Showing Up in Inflation. Why Trump Can’t Afford to Ditch Powell.
House deals a blow to “Crypto Week,” ASML warns on 2026 growth, a promising Chinese weight-loss drug, and more news to start your day.
Biocon eyes generic Wegovy obesity drug launch in India, Canada in next 2 years, CEO says
Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...
The Daily Reflector4h
ROSEN, GLOBAL INVESTOR RIGHTS COUNSEL, Encourages Hims & Hers Health, Inc. Investors to ...
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive (the ...